ADXS- Data looks very good here, probably at least 2 indications will be approved for them down the road so the valuation is very low. I'm expecting this to do well when the Summer conferences start and the focus is on biotech. Whether the Summer gains will hold I don't know, may be a couple year investment until it pays off big. It's a little over sold but could inch down a little more before starts to move up with the sector.